Form 4: Denali Therapeutics Director Steve Krognes Reports Acquisition of Shares and Stock Options
SEC Form 4 Filing
Director Steve Krognes reports acquisition of Denali Therapeutics stock and options, including restricted stock units and options vesting within one year.
Summary
- On May 31, 2024, Steve E. Krognes, a director of Denali Therapeutics Inc., reported the acquisition of 5,967 shares of common stock represented by Restricted Stock Units (RSUs) and a contingent right to receive one share of common stock.
- These RSUs will vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
- Krognes also acquired 17,901 stock options with an exercise price of $18.56, which also vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
- Following these transactions, Krognes directly owns 53,308 shares, including 18,467 unvested RSUs, and indirectly owns 850,000 shares through The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which he serves as trustee.
- He also directly owns 17,901 stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine transaction.
Positives
- The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.
- The vesting schedule of the RSUs and stock options aligns with a one-year timeframe, potentially incentivizing the director to contribute to the company's success over the coming year.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry. Monitoring such filings can provide insights into management's sentiment and confidence in the company's performance.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 01/25/2016 | Date of The Steve Edward Krognes Revocable Trust U/A DTD |
| 05/31/2024 | Date of transaction: Acquisition of shares and stock options |
| 05/31/2034 | Expiration date of stock options |
| 06/04/2024 | Date of signature on the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.